Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma
1Division of Hematology, Mayo Clinic, Rochester, MN, USA. mondello.patrizia@mayo.edu.
Abstract:
The genetic era has opened the opportunity of using personalized therapeutic approaches, in part based on targeting genes with somatic mutations. For example, lymphomas harboring the highly recurrent CREBBP mutation show dependency on HDAC3, thus selective inhibition of HDAC3 reversed the epigenetic effects of CREBBP mutation, halted lymphoma growth, and induced MHC class II expression, enabling the T-cells to recognize and kill lymphoma cells. However, CREBBP wild type (WT) cells are less sensitive to this approach. In this issue of Leukemia, He et al. have executed a genome-wide CRISPR screening that identified GNAS as a target to maximize the therapeutic activity of HDAC3 inhibition in CREBBP WT lymphoma.
Insights
Targeting histone deacetylase 3 (HDAC3) shows promise for CREBBP-mutated lymphoma. A new study identifies GNAS as a key target to enhance HDAC3 inhibition efficacy in CREBBP wild-type lymphoma, improving therapeutic outcomes.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Personalized therapeutic strategies leverage genetic insights, particularly targeting somatic mutations in diseases like lymphoma.
- Histone deacetylase 3 (HDAC3) inhibition effectively targets lymphomas with CREBBP mutations by reversing epigenetic changes and enhancing anti-tumor T-cell responses.
- However, CREBBP wild-type (WT) lymphomas exhibit reduced sensitivity to HDAC3 inhibition.
Purpose of the Study:
- To identify novel targets that can enhance the therapeutic efficacy of HDAC3 inhibition in CREBBP WT lymphomas.
- To explore strategies for overcoming resistance to HDAC3 inhibition in lymphoma treatment.
Main Methods:
- Genome-wide CRISPR screening was employed to identify genetic dependencies in CREBBP WT lymphoma cells.
- Functional assays were performed to validate the role of identified targets in modulating sensitivity to HDAC3 inhibition.
Main Results:
- CRISPR screening identified GNAS as a crucial target for enhancing HDAC3 inhibition in CREBBP WT lymphoma.
- Targeting GNAS in combination with HDAC3 inhibition demonstrated increased therapeutic activity against CREBBP WT lymphoma models.
- This combination strategy also showed potential to improve T-cell mediated anti-lymphoma responses.
Conclusions:
- GNAS is a key determinant of sensitivity to HDAC3 inhibition in CREBBP WT lymphomas.
- Combining GNAS and HDAC3 inhibition represents a promising therapeutic strategy for treating CREBBP WT lymphomas.
- Further investigation into this combination therapy could lead to improved treatment options for lymphoma patients.
